Search Results

Rampart Bioscience was working on a platform to deliver gene therapies without the need for viral vectors.

Rampart Bioscience, Inc., a biotechnology company developing next-generation biologics, announced an $85 million Series A financing to create medicines that aim to unburden patients from disease and their treatments.

South Rampart Pharma, Inc. announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma, will present the latest clinical and scientific data on its lead clinical asset at Biotech Showcase 2024 on Tuesday, January 9.

Crossject provides additional, clinically meaningful perspectives on ZEPIZURE® in light of its recently published bioequivalence study results and of the conclusions and hints by the authors of the RAMPART study1, a landmark double-blind randomized clinical trial comparing the efficacy of IM midazolam vs. IV lorazepam in the pre-hospital treatment of status epilepticus by paramedics.

South Rampart Pharma, Inc., announced the publication of a paper in Scientific Reports describing the manner in which SRP-001 works in the brain to alleviate pain and the results of a Phase 1 randomized controlled trial 1.

South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company developing SRP-001, a first-in-class non-opioid candidate for the treatment of chronic and acute pain, today announced the Company’s executive team will be participating in the upcoming investor events throughout October 2023.

South Rampart Pharma, Inc. announced today that it has successfully completed a Phase 1 trial (NCT05484414).

South Rampart Pharma, Inc. (“South Rampart” or the “Company”) today announced that the China National Intellectual Property Administration (CNIPA) has granted the Company a new patent covering the composition of matter of SRP-001, South Rampart’s novel, non-opioid new chemical entity that avoids the liver toxicity associated with acetaminophen.

South Rampart Pharma, Inc. announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023.